The Experts below are selected from a list of 1353 Experts worldwide ranked by ideXlab platform

Cindy M. Meston - One of the best experts on this subject based on the ideXlab platform.

  • heart rate variability biofeedback increases Sexual Arousal among women with female Sexual Arousal Disorder results from a randomized controlled trial
    Behaviour Research and Therapy, 2019
    Co-Authors: Ryan L Boyd, Amelia M Stanton, Justin J Fogarty, Cindy M. Meston
    Abstract:

    Abstract Low resting heart rate variability (HRV) has been associated with poor Sexual Arousal function in women. In a recent study, a single session of autogenic training increased HRV and facilitated improvements in both Sexual Arousal and perceived genital sensations among women experiencing decreased Arousal. The current study expands upon these findings by examining the efficacy of HRV biofeedback, with and without autogenic training, as a treatment for Sexual Arousal dysfunction in an at-home setting. Participants (N = 78) were randomized into one of three conditions: HRV biofeedback, HRV biofeedback + autogenic training, or waitlist control. Each condition included three laboratory sessions; participants in the two active conditions completed 4–6 biofeedback sessions at home, and participants in the HRVB + A condition listened to a 14-min autogenic training recording before completing the biofeedback. Across the three laboratory visits, participants in the three conditions singficnatly differed in their genital Arousal, subjective Sexual Arousal, and their perceived genital sensations. Compared to women in the control group, women who engaged in HRV biofeedback at home, with and without additional autogenic training, experienced increases in genital Arousal, subjective Sexual Arousal, and perceived genital sensations. These results provide preliminary support for the contribution of heart rate variability level to female Sexual Arousal function and for the use of either of these interventions in the treatment of Sexual Arousal concerns.

  • The Sensitivity of Continuous Laboratory Measures of Physiological and Subjective Sexual Arousal for Diagnosing Women with Sexual Arousal Disorder
    The Journal of Sexual Medicine, 2010
    Co-Authors: Cindy M. Meston, Alessandra H. Rellini, Katie Mccall
    Abstract:

    Introduction. Past findings on the diagnostic sensitivity of vaginal photoplethysmography are limited by testing among women with heterogeneous Sexual dysfunctions and by the use of statistical techniques that are unable to assess how changes in subjective Arousal are associated with changes in physiological Arousal. Aims. The aims of this study were to: (i) test the sensitivity of vaginal photoplethysmography and continuous measures of subjective Sexual Arousal in differentiating between women with and without Sexual Arousal or orgasm dysfunction; and (ii) examine the diagnostic utility of measuring the synchrony between genital and subjective Sexual responses. Methods. Sexual Arousal was assessed in Sexually healthy women (n = 12), women with orgasm Disorder (OD; n = 12), and 38 women who met the criteria for the three subcategories of Sexual Arousal dysfunction described by Basson et al. (i.e., genital Sexual Arousal Disorder (GAD; n = 9), subjective Sexual Arousal Disorder (SAD; n = 13), and combined genital and subjective Arousal Disorder (CAD; n = 16)). Main Outcome Measures. Physiological Sexual Arousal was assessed using vaginal photoplethysmography, and subjective Sexual Arousal was measured continuously and using a Likert-scale in response to Sexual videos. Results. Women with GAD showed the lowest and women with CAD showed the highest levels of vaginal pulse amplitude response to erotic stimuli. Women with Sexual Arousal Disorder showed significantly lower levels of subjective Sexual Arousal to erotic stimuli than did Sexually healthy women. Relations between subjective and physiological measures of Sexual Arousal were significantly weaker among women with Sexual Arousal Disorder than Sexually healthy women or women with OD. Conclusion. Preliminary support was provided for the diagnostic utility of measuring the synchrony between subjective and genital Arousal in women with Sexual Arousal Disorder. Findings do not support the sensitivity of using vaginal photoplethysmography, or continuous or Likert-scale measures of subjective Arousal for differentiating between subtypes of women with Sexual Arousal Disorder. Meston CM, Rellini AH, and McCall K. The sensitivity of continuous laboratory measures of physiological and subjective Sexual Arousal for diagnosing women with Sexual Arousal Disorder. J Sex Med 2010;7:938-950.

  • The sensitivity of continuous laboratory measures of physiological and subjective Sexual Arousal for diagnosing women with Sexual Arousal Disorder.
    The journal of sexual medicine, 2010
    Co-Authors: Cindy M. Meston, Alessandra H. Rellini, Katie Mccall
    Abstract:

    Past findings on the diagnostic sensitivity of vaginal photoplethysmography are limited by testing among women with heterogeneous Sexual dysfunctions and by the use of statistical techniques that are unable to assess how changes in subjective Arousal are associated with changes in physiological Arousal. The aims of this study were to: (i) test the sensitivity of vaginal photoplethysmography and continuous measures of subjective Sexual Arousal in differentiating between women with and without Sexual Arousal or orgasm dysfunction; and (ii) examine the diagnostic utility of measuring the synchrony between genital and subjective Sexual responses. Sexual Arousal was assessed in Sexually healthy women (n = 12), women with orgasm Disorder (OD; n = 12), and 38 women who met the criteria for the three subcategories of Sexual Arousal dysfunction described by Basson et al. (i.e., genital Sexual Arousal Disorder [GAD; n = 9], subjective Sexual Arousal Disorder [SAD; n = 13], and combined genital and subjective Arousal Disorder [CAD; n = 16]). Physiological Sexual Arousal was assessed using vaginal photoplethysmography, and subjective Sexual Arousal was measured continuously and using a Likert-scale in response to Sexual videos. Women with GAD showed the lowest and women with CAD showed the highest levels of vaginal pulse amplitude response to erotic stimuli. Women with Sexual Arousal Disorder showed significantly lower levels of subjective Sexual Arousal to erotic stimuli than did Sexually healthy women. Relations between subjective and physiological measures of Sexual Arousal were significantly weaker among women with Sexual Arousal Disorder than Sexually healthy women or women with OD. Preliminary support was provided for the diagnostic utility of measuring the synchrony between subjective and genital Arousal in women with Sexual Arousal Disorder. Findings do not support the sensitivity of using vaginal photoplethysmography, or continuous or Likert-scale measures of subjective Arousal for differentiating between subtypes of women with Sexual Arousal Disorder.

  • Short- and Long-term Effects of Ginkgo Biloba Extract on Sexual Dysfunction in Women
    Archives of Sexual Behavior, 2008
    Co-Authors: Cindy M. Meston, Alessandra H. Rellini, Michael J. Telch
    Abstract:

    Ginkgo biloba extract (GBE) facilitates blood flow, influences nitric oxide systems, and has a relaxant effect on smooth muscle tissue. These processes are important to the Sexual response in women and, hence, it is feasible that GBE may have a therapeutic effect. The present study was the first to provide an empirical examination of the effects of both short- and long-term GBE administration on subjective and physiological (vaginal photoplethysmography) measures of Sexual function in women with Sexual Arousal Disorder. A single dose of 300 mg GBE had a small but significant facilitatory effect on physiological, but not subjective, Sexual Arousal compared to placebo in 99 Sexually dysfunctional women. The long-term effects of GBE on Sexual function were assessed in 68 Sexually dysfunctional women who were randomly assigned to 8 weeks treatment of either (1) GBE (300 mg/daily), (2) placebo, (3) sex therapy which focused on training women to attend to genital sensations, or (4) sex therapy plus GBE. When combined with sex therapy, but not alone, long-term GBE treatment significantly increased Sexual desire and contentment beyond placebo. Sex therapy alone significantly enhanced orgasm function compared with placebo. Long-term GBE administration did not significantly enhance Arousal responses beyond placebo. It was concluded that (1) neither short- or long-term administration of GBE alone substantially impacts Sexual function in women, (2) a substantial placebo effect on Sexual function exists in women with Sexual concerns, and (3) teaching women to focus on genital sensations during sex enhances certain aspects of women’s Sexual functioning.

  • The Effects of False Positive and False Negative Physiological Feedback on Sexual Arousal: A Comparison of Women with or without Sexual Arousal Disorder
    Archives of Sexual Behavior, 2007
    Co-Authors: Katie M. Mccall, Cindy M. Meston
    Abstract:

    The effects of false positive and false negative physiological feedback (vaginal photoplethymograph response print-out) on women's Sexual Arousal were examined. Participants included women without Sexual dysfunction ( n =16) and women with Sexual Arousal Disorder (SAD; n =15). Measures of subjective Sexual Arousal, physiological Sexual Arousal (vaginal pulse amplitude), expectancies, affect, and anxiety were obtained in response to viewing an erotic film. Results indicated that false positive feedback significantly increased subjective levels of Sexual Arousal, whereas false negative feedback significantly decreased subjective levels of Sexual Arousal in both groups. Sexually functional women had overall higher expectancies for Sexual Arousal than women with SAD. Unexpectedly, false positive feedback did not significantly impact physiological Sexual Arousal in Sexually functional women; however, it resulted in significantly decreased responses in physiological Sexual Arousal in women with SAD. False negative feedback had no significant effect on physiological Sexual response in Sexually functional women or women with SAD.

Antonio Cianci - One of the best experts on this subject based on the ideXlab platform.

  • randomized crossover study investigating daily versus on demand vulvar visnadine spray in women affected by female Sexual Arousal Disorder
    Gynecological Endocrinology, 2018
    Co-Authors: Salvatore Caruso, Diletta Mauro, M. Cariola, V. Fava, Agnese Maria Chiara Rapisarda, Antonio Cianci
    Abstract:

    AbstractThe aim of the study was to verify the efficacy of vulvar Visnadine spray in premenopausal women affected by female Sexual Arousal Disorder (FSAD). Thirty-eight women aged 25–40 years affected by FSAD were enrolled in the randomized crossover study, by two possible sequences: on-demand, washout, daily (A sequence); and daily, washout, on-demand (B sequence). The Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS) were used to assess Sexual function and Sexual distress, respectively. Color Doppler ultrasonography was used to measure clitoral blood flow. The study had two follow-ups at 30 (T1) and 60 days (T2). Thirty-one women completed the study. Mean (SD) Sexual activity and vulvar Visnadine spray usage was 1 ± 0.9 weekly during on-demand administration for both the sequences (Vs T0, p = NS). The mean Sexual activity during daily usage was 2 ± 0.9 (Vs T0, p < .004) and 2 ± 0.8 (Vs T0, p < .001) for A and B sequences, respectively. FSFI total score, particularly genital...

  • Randomized crossover study investigating daily versus on-demand vulvar Visnadine spray in women affected by female Sexual Arousal Disorder.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2017
    Co-Authors: Salvatore Caruso, Diletta Mauro, M. Cariola, V. Fava, Agnese Maria Chiara Rapisarda, Antonio Cianci
    Abstract:

    AbstractThe aim of the study was to verify the efficacy of vulvar Visnadine spray in premenopausal women affected by female Sexual Arousal Disorder (FSAD). Thirty-eight women aged 25–40 years affected by FSAD were enrolled in the randomized crossover study, by two possible sequences: on-demand, washout, daily (A sequence); and daily, washout, on-demand (B sequence). The Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS) were used to assess Sexual function and Sexual distress, respectively. Color Doppler ultrasonography was used to measure clitoral blood flow. The study had two follow-ups at 30 (T1) and 60 days (T2). Thirty-one women completed the study. Mean (SD) Sexual activity and vulvar Visnadine spray usage was 1 ± 0.9 weekly during on-demand administration for both the sequences (Vs T0, p = NS). The mean Sexual activity during daily usage was 2 ± 0.9 (Vs T0, p 

  • Sildenafil improves Sexual functioning in premenopausal women with type 1 diabetes who are affected by Sexual Arousal Disorder: a double-blind, crossover, placebo-controlled pilot study
    Fertility and sterility, 2006
    Co-Authors: Salvatore Caruso, Salvatore Rugolo, Carmela Agnello, Giorgia Intelisano, Lucia Di Mari, Antonio Cianci
    Abstract:

    Objective To verify whether sildenafil is effective in type 1 premenopausal women affected by Sexual Arousal Disorder (SAD). Design Double-blind, crossover, placebo-controlled study. Setting Gynecological diabetic outpatient clinic and Sexual clinic. Patient(s) Thirty-six type 1 premenopausal diabetic women affected by SAD. Intervention(s) Two 8-week periods of sildenafil 100 mg, washout, and placebo, by two possible sequences. Main Outcomes Measure(s) Each woman submitted blood samples to measure HbA 1c , and T, free T (FT), and PRL. Efficacy was assessed [1] subjectively by the Personal Experiences Questionnaire based on the 5-point Likert scale, quantifying Arousal, desire, orgasm, enjoyment of Sexual activities, and frequency of Sexual relationships; and [2] objectively by translabial color Doppler ultrasound to measure the resistance index (RI), pulsatility index (PI), peak systolic velocity (PSV), and end diastolic velocity of clitoral arteries. Result(s) Thirty-two women completed the study. The mean HbA 1c value was 8.0% ± 1.8%, and plasma concentrations of T, FT, and PRL were normal. Sildenafil seems to improve Arousal, orgasm and Sexual enjoyment, and dyspareunia in women affected by type 1 diabetes. However, by flowmetric measurements, the mean RI was significantly lower and both the mean PI and PSV of the clitoral arteries were significantly higher compared with baseline and placebo. Conclusion(s) Sildenafil seems to improve subjective Sexual aspects and can be used to treat objectively genital Arousal Disorder of premenopausal women with type 1 diabetes.

  • placebo controlled study on efficacy and safety of daily apomorphine sl intake in premenopausal women affected by hypoactive Sexual desire Disorder and Sexual Arousal Disorder
    Urology, 2004
    Co-Authors: Salvatore Caruso, Carmela Agnello, Giorgia Intelisano, Lucia Di Mari, M Farina, Antonio Cianci
    Abstract:

    Abstract Objectives To verify whether apomorphine SL is effective in premenopausal women affected by Arousal Disorder with hypoactive Sexual desire Disorder. Methods Sixty-two volunteer women, aged 26 to 45 years, affected by Arousal Disorders and hypoactive Sexual desire Disorder participated in the study, which consisted of two parts. The first was 4 weeks of a taken-as-needed, open-label, dose-escalation regimen starting at 2 or 3 mg of apomorphine SL. The second part of the study was for the nonresponders, who were randomly allocated to treatment in one of six possible sequences of three 2-week double-blind, crossover study periods with apomorphine 2 mg or 3 mg, washout, and placebo. Efficacy was assessed with the Personal Experiences Questionnaire using the 5-point Likert scale. The Personal Experiences Questionnaire quantified subjective Arousal, desire, orgasm, enjoyment, and frequency of Sexual relationships. Results Fifty women completed the 4-week "as required" drug regimen, and 6 of them benefited from this treatment regimen ( P P P Conclusions The results of our study suggest that daily apomorphine SL may improve the Sexual life of women affected by Sexual difficulties. Additional studies are needed to define the daily use of apomorphine SL in large subgroups of women on the basis of etiology and the severity of Sexual dysfunction.

Salvatore Caruso - One of the best experts on this subject based on the ideXlab platform.

  • randomized crossover study investigating daily versus on demand vulvar visnadine spray in women affected by female Sexual Arousal Disorder
    Gynecological Endocrinology, 2018
    Co-Authors: Salvatore Caruso, Diletta Mauro, M. Cariola, V. Fava, Agnese Maria Chiara Rapisarda, Antonio Cianci
    Abstract:

    AbstractThe aim of the study was to verify the efficacy of vulvar Visnadine spray in premenopausal women affected by female Sexual Arousal Disorder (FSAD). Thirty-eight women aged 25–40 years affected by FSAD were enrolled in the randomized crossover study, by two possible sequences: on-demand, washout, daily (A sequence); and daily, washout, on-demand (B sequence). The Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS) were used to assess Sexual function and Sexual distress, respectively. Color Doppler ultrasonography was used to measure clitoral blood flow. The study had two follow-ups at 30 (T1) and 60 days (T2). Thirty-one women completed the study. Mean (SD) Sexual activity and vulvar Visnadine spray usage was 1 ± 0.9 weekly during on-demand administration for both the sequences (Vs T0, p = NS). The mean Sexual activity during daily usage was 2 ± 0.9 (Vs T0, p < .004) and 2 ± 0.8 (Vs T0, p < .001) for A and B sequences, respectively. FSFI total score, particularly genital...

  • Randomized crossover study investigating daily versus on-demand vulvar Visnadine spray in women affected by female Sexual Arousal Disorder.
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2017
    Co-Authors: Salvatore Caruso, Diletta Mauro, M. Cariola, V. Fava, Agnese Maria Chiara Rapisarda, Antonio Cianci
    Abstract:

    AbstractThe aim of the study was to verify the efficacy of vulvar Visnadine spray in premenopausal women affected by female Sexual Arousal Disorder (FSAD). Thirty-eight women aged 25–40 years affected by FSAD were enrolled in the randomized crossover study, by two possible sequences: on-demand, washout, daily (A sequence); and daily, washout, on-demand (B sequence). The Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS) were used to assess Sexual function and Sexual distress, respectively. Color Doppler ultrasonography was used to measure clitoral blood flow. The study had two follow-ups at 30 (T1) and 60 days (T2). Thirty-one women completed the study. Mean (SD) Sexual activity and vulvar Visnadine spray usage was 1 ± 0.9 weekly during on-demand administration for both the sequences (Vs T0, p = NS). The mean Sexual activity during daily usage was 2 ± 0.9 (Vs T0, p 

  • Sildenafil improves Sexual functioning in premenopausal women with type 1 diabetes who are affected by Sexual Arousal Disorder: a double-blind, crossover, placebo-controlled pilot study
    Fertility and sterility, 2006
    Co-Authors: Salvatore Caruso, Salvatore Rugolo, Carmela Agnello, Giorgia Intelisano, Lucia Di Mari, Antonio Cianci
    Abstract:

    Objective To verify whether sildenafil is effective in type 1 premenopausal women affected by Sexual Arousal Disorder (SAD). Design Double-blind, crossover, placebo-controlled study. Setting Gynecological diabetic outpatient clinic and Sexual clinic. Patient(s) Thirty-six type 1 premenopausal diabetic women affected by SAD. Intervention(s) Two 8-week periods of sildenafil 100 mg, washout, and placebo, by two possible sequences. Main Outcomes Measure(s) Each woman submitted blood samples to measure HbA 1c , and T, free T (FT), and PRL. Efficacy was assessed [1] subjectively by the Personal Experiences Questionnaire based on the 5-point Likert scale, quantifying Arousal, desire, orgasm, enjoyment of Sexual activities, and frequency of Sexual relationships; and [2] objectively by translabial color Doppler ultrasound to measure the resistance index (RI), pulsatility index (PI), peak systolic velocity (PSV), and end diastolic velocity of clitoral arteries. Result(s) Thirty-two women completed the study. The mean HbA 1c value was 8.0% ± 1.8%, and plasma concentrations of T, FT, and PRL were normal. Sildenafil seems to improve Arousal, orgasm and Sexual enjoyment, and dyspareunia in women affected by type 1 diabetes. However, by flowmetric measurements, the mean RI was significantly lower and both the mean PI and PSV of the clitoral arteries were significantly higher compared with baseline and placebo. Conclusion(s) Sildenafil seems to improve subjective Sexual aspects and can be used to treat objectively genital Arousal Disorder of premenopausal women with type 1 diabetes.

  • placebo controlled study on efficacy and safety of daily apomorphine sl intake in premenopausal women affected by hypoactive Sexual desire Disorder and Sexual Arousal Disorder
    Urology, 2004
    Co-Authors: Salvatore Caruso, Carmela Agnello, Giorgia Intelisano, Lucia Di Mari, M Farina, Antonio Cianci
    Abstract:

    Abstract Objectives To verify whether apomorphine SL is effective in premenopausal women affected by Arousal Disorder with hypoactive Sexual desire Disorder. Methods Sixty-two volunteer women, aged 26 to 45 years, affected by Arousal Disorders and hypoactive Sexual desire Disorder participated in the study, which consisted of two parts. The first was 4 weeks of a taken-as-needed, open-label, dose-escalation regimen starting at 2 or 3 mg of apomorphine SL. The second part of the study was for the nonresponders, who were randomly allocated to treatment in one of six possible sequences of three 2-week double-blind, crossover study periods with apomorphine 2 mg or 3 mg, washout, and placebo. Efficacy was assessed with the Personal Experiences Questionnaire using the 5-point Likert scale. The Personal Experiences Questionnaire quantified subjective Arousal, desire, orgasm, enjoyment, and frequency of Sexual relationships. Results Fifty women completed the 4-week "as required" drug regimen, and 6 of them benefited from this treatment regimen ( P P P Conclusions The results of our study suggest that daily apomorphine SL may improve the Sexual life of women affected by Sexual difficulties. Additional studies are needed to define the daily use of apomorphine SL in large subgroups of women on the basis of etiology and the severity of Sexual dysfunction.

  • premenopausal women affected by Sexual Arousal Disorder treated with sildenafil a double blind cross over placebo controlled study
    British Journal of Obstetrics and Gynaecology, 2001
    Co-Authors: Salvatore Caruso, Giorgia Intelisano, Lorenzo Lupo, Carmela Agnello
    Abstract:

    Objective To verify whether sildenafil is effective in young premenopausal women affected by Arousal Disorder. Design A double-blind cross-over study. Setting Centre for Sexological Research, Department of Microbiological and Gynaecological Science, University of Catania, Italy. Sample Fifty-three volunteer women aged 22–28 years affected by Arousal Disorders. Methods The study consisted of three 4-week periods: sildenafil, washout, placebo, by six possible sequences. sildenafil was used at 25 mg or 50 mg. Main outcome measures Efficacy was assessed at baseline and once monthly by the Personal Experiences Questionnaire based on the 5-point Likert scale. The questionnaire quantified subjective Arousal (primary endpoint), and orgasm, enjoyment, Sexual frequency, and the number of Sexual fantasies. Results Fifty-one women completed the study. Mean (SD) usage of sildenafil 25mg and 50mg was, respectively, 2.8 (0.8) and 2.7 (1.3) times weekly, while mean usage of placebo was 2.8 (1.6) times weekly. During both sildenafil dosages, Arousal and orgasm improved with respect to placebo (P<0.001). Therapeutically significant differences were not noted during the treatment with both 50 mg and 25 mg of sildenafil for Arousal and orgasm. The frequency of Sexual fantasies and of Sexual intercourse, and enjoyment, improved in the women treated with sildenafil (P<0.05). Conclusions Our study suggests that sildenafil may improve Sexual performance of women affected by Sexual difficulties such as Arousal Disorder, and may indirectly improve other aspects of Sexual life. Moreover, further studies need to define the use of PDE type 5 inhibitors in this Sexual pathophysiology.

Alessandra H. Rellini - One of the best experts on this subject based on the ideXlab platform.

  • The Sensitivity of Continuous Laboratory Measures of Physiological and Subjective Sexual Arousal for Diagnosing Women with Sexual Arousal Disorder
    The Journal of Sexual Medicine, 2010
    Co-Authors: Cindy M. Meston, Alessandra H. Rellini, Katie Mccall
    Abstract:

    Introduction. Past findings on the diagnostic sensitivity of vaginal photoplethysmography are limited by testing among women with heterogeneous Sexual dysfunctions and by the use of statistical techniques that are unable to assess how changes in subjective Arousal are associated with changes in physiological Arousal. Aims. The aims of this study were to: (i) test the sensitivity of vaginal photoplethysmography and continuous measures of subjective Sexual Arousal in differentiating between women with and without Sexual Arousal or orgasm dysfunction; and (ii) examine the diagnostic utility of measuring the synchrony between genital and subjective Sexual responses. Methods. Sexual Arousal was assessed in Sexually healthy women (n = 12), women with orgasm Disorder (OD; n = 12), and 38 women who met the criteria for the three subcategories of Sexual Arousal dysfunction described by Basson et al. (i.e., genital Sexual Arousal Disorder (GAD; n = 9), subjective Sexual Arousal Disorder (SAD; n = 13), and combined genital and subjective Arousal Disorder (CAD; n = 16)). Main Outcome Measures. Physiological Sexual Arousal was assessed using vaginal photoplethysmography, and subjective Sexual Arousal was measured continuously and using a Likert-scale in response to Sexual videos. Results. Women with GAD showed the lowest and women with CAD showed the highest levels of vaginal pulse amplitude response to erotic stimuli. Women with Sexual Arousal Disorder showed significantly lower levels of subjective Sexual Arousal to erotic stimuli than did Sexually healthy women. Relations between subjective and physiological measures of Sexual Arousal were significantly weaker among women with Sexual Arousal Disorder than Sexually healthy women or women with OD. Conclusion. Preliminary support was provided for the diagnostic utility of measuring the synchrony between subjective and genital Arousal in women with Sexual Arousal Disorder. Findings do not support the sensitivity of using vaginal photoplethysmography, or continuous or Likert-scale measures of subjective Arousal for differentiating between subtypes of women with Sexual Arousal Disorder. Meston CM, Rellini AH, and McCall K. The sensitivity of continuous laboratory measures of physiological and subjective Sexual Arousal for diagnosing women with Sexual Arousal Disorder. J Sex Med 2010;7:938-950.

  • The sensitivity of continuous laboratory measures of physiological and subjective Sexual Arousal for diagnosing women with Sexual Arousal Disorder.
    The journal of sexual medicine, 2010
    Co-Authors: Cindy M. Meston, Alessandra H. Rellini, Katie Mccall
    Abstract:

    Past findings on the diagnostic sensitivity of vaginal photoplethysmography are limited by testing among women with heterogeneous Sexual dysfunctions and by the use of statistical techniques that are unable to assess how changes in subjective Arousal are associated with changes in physiological Arousal. The aims of this study were to: (i) test the sensitivity of vaginal photoplethysmography and continuous measures of subjective Sexual Arousal in differentiating between women with and without Sexual Arousal or orgasm dysfunction; and (ii) examine the diagnostic utility of measuring the synchrony between genital and subjective Sexual responses. Sexual Arousal was assessed in Sexually healthy women (n = 12), women with orgasm Disorder (OD; n = 12), and 38 women who met the criteria for the three subcategories of Sexual Arousal dysfunction described by Basson et al. (i.e., genital Sexual Arousal Disorder [GAD; n = 9], subjective Sexual Arousal Disorder [SAD; n = 13], and combined genital and subjective Arousal Disorder [CAD; n = 16]). Physiological Sexual Arousal was assessed using vaginal photoplethysmography, and subjective Sexual Arousal was measured continuously and using a Likert-scale in response to Sexual videos. Women with GAD showed the lowest and women with CAD showed the highest levels of vaginal pulse amplitude response to erotic stimuli. Women with Sexual Arousal Disorder showed significantly lower levels of subjective Sexual Arousal to erotic stimuli than did Sexually healthy women. Relations between subjective and physiological measures of Sexual Arousal were significantly weaker among women with Sexual Arousal Disorder than Sexually healthy women or women with OD. Preliminary support was provided for the diagnostic utility of measuring the synchrony between subjective and genital Arousal in women with Sexual Arousal Disorder. Findings do not support the sensitivity of using vaginal photoplethysmography, or continuous or Likert-scale measures of subjective Arousal for differentiating between subtypes of women with Sexual Arousal Disorder.

  • Short- and Long-term Effects of Ginkgo Biloba Extract on Sexual Dysfunction in Women
    Archives of Sexual Behavior, 2008
    Co-Authors: Cindy M. Meston, Alessandra H. Rellini, Michael J. Telch
    Abstract:

    Ginkgo biloba extract (GBE) facilitates blood flow, influences nitric oxide systems, and has a relaxant effect on smooth muscle tissue. These processes are important to the Sexual response in women and, hence, it is feasible that GBE may have a therapeutic effect. The present study was the first to provide an empirical examination of the effects of both short- and long-term GBE administration on subjective and physiological (vaginal photoplethysmography) measures of Sexual function in women with Sexual Arousal Disorder. A single dose of 300 mg GBE had a small but significant facilitatory effect on physiological, but not subjective, Sexual Arousal compared to placebo in 99 Sexually dysfunctional women. The long-term effects of GBE on Sexual function were assessed in 68 Sexually dysfunctional women who were randomly assigned to 8 weeks treatment of either (1) GBE (300 mg/daily), (2) placebo, (3) sex therapy which focused on training women to attend to genital sensations, or (4) sex therapy plus GBE. When combined with sex therapy, but not alone, long-term GBE treatment significantly increased Sexual desire and contentment beyond placebo. Sex therapy alone significantly enhanced orgasm function compared with placebo. Long-term GBE administration did not significantly enhance Arousal responses beyond placebo. It was concluded that (1) neither short- or long-term administration of GBE alone substantially impacts Sexual function in women, (2) a substantial placebo effect on Sexual function exists in women with Sexual concerns, and (3) teaching women to focus on genital sensations during sex enhances certain aspects of women’s Sexual functioning.

  • original research outcomes research the sensitivity of event logs self administered questionnaires and photoplethysmography to detect treatment induced changes in female Sexual Arousal Disorder fsad diagnosis
    The Journal of Sexual Medicine, 2006
    Co-Authors: Alessandra H. Rellini, Cindy M. Meston
    Abstract:

    ABSTRACT Introduction The literature provides little evidence on what type of endpoints should be used to assess treatment‐induced improvement in female Sexual function. Aim The main goal of this study was to provide empiric evidence on the sensitivity of different types of measures for detecting treatment‐induced changes in female Sexual dysfunction diagnosis. Methods The measures investigated in this study included event logs, self‐administered questionnaires (Female Sexual Functioning Index; FSFI), vaginal photoplethysmography, and continuous subjective Sexual Arousal measured during exposure to erotic videos. Participants were 24 women with female Sexual Arousal Disorder (FSAD) who received sex therapy, placebo, or gingko biloba in a four‐arm double‐blind placebo‐controlled clinical trial. FSAD was diagnosed utilizing a semistructured interview administered at pre‐ and post‐treatment. Those women who did not meet FSAD criteria at post‐treatment (N = 10) were labeled as “improved,” while women who still met FSAD criteria (N = 14) were categorized as “not improved” even if they showed signs of improvements. Main Outcome Measure Change scores from pre‐ to post‐treatment on the FSFI, event logs, vaginal photoplethysmography, and continuous subjective levels of Sexual Arousal were used to predict whether women improved at post‐treatment. Results were checked with exact logistic regression to control for the small sample size. Results .  The FSFI was the only measure to significantly predict whether women improved at post‐treatment. The findings from this study lend support for the use of validated questionnaires as endpoint criteria in detecting treatment‐induced changes in women's Sexual dysfunction. Rellini A, and Meston C. The sensitivity of event logs, self‐administered questionnaires and photoplethysmography to detect treatment‐induced changes in female Sexual Arousal Disorder (FSAD) diagnosis. J Sex Med 2006;3:283–291.

  • ORIGINAL RESEARCH—OUTCOMES RESEARCH: The Sensitivity of Event Logs, Self‐Administered Questionnaires and Photoplethysmography to Detect Treatment‐Induced Changes in Female Sexual Arousal Disorder (FSAD) Diagnosis
    The journal of sexual medicine, 2006
    Co-Authors: Alessandra H. Rellini, Cindy M. Meston
    Abstract:

    ABSTRACT Introduction The literature provides little evidence on what type of endpoints should be used to assess treatment‐induced improvement in female Sexual function. Aim The main goal of this study was to provide empiric evidence on the sensitivity of different types of measures for detecting treatment‐induced changes in female Sexual dysfunction diagnosis. Methods The measures investigated in this study included event logs, self‐administered questionnaires (Female Sexual Functioning Index; FSFI), vaginal photoplethysmography, and continuous subjective Sexual Arousal measured during exposure to erotic videos. Participants were 24 women with female Sexual Arousal Disorder (FSAD) who received sex therapy, placebo, or gingko biloba in a four‐arm double‐blind placebo‐controlled clinical trial. FSAD was diagnosed utilizing a semistructured interview administered at pre‐ and post‐treatment. Those women who did not meet FSAD criteria at post‐treatment (N = 10) were labeled as “improved,” while women who still met FSAD criteria (N = 14) were categorized as “not improved” even if they showed signs of improvements. Main Outcome Measure Change scores from pre‐ to post‐treatment on the FSFI, event logs, vaginal photoplethysmography, and continuous subjective levels of Sexual Arousal were used to predict whether women improved at post‐treatment. Results were checked with exact logistic regression to control for the small sample size. Results .  The FSFI was the only measure to significantly predict whether women improved at post‐treatment. The findings from this study lend support for the use of validated questionnaires as endpoint criteria in detecting treatment‐induced changes in women's Sexual dysfunction. Rellini A, and Meston C. The sensitivity of event logs, self‐administered questionnaires and photoplethysmography to detect treatment‐induced changes in female Sexual Arousal Disorder (FSAD) diagnosis. J Sex Med 2006;3:283–291.

Scott Haughie - One of the best experts on this subject based on the ideXlab platform.

  • Influence of sildenafil on genital engorgement in women with female Sexual Arousal Disorder.
    The journal of sexual medicine, 2012
    Co-Authors: Laura Leddy, Claire C. Yang, Bronwyn G. A. Stuckey, Maria Sudworth, Scott Haughie, Stefan Sultana, Kenneth R. Maravilla
    Abstract:

    ABSTRACT Introduction We previously described dynamic, noncontrast magnetic resonance imaging (MRI) of the female genitalia as a reproducible, nonintrusive, objective means of quantifying Sexual Arousal response in women without Sexual difficulties. These studies showed an increase in clitoral engorgement ranging from 50 to 300% in healthy women during Sexual Arousal. Aim This study sought to evaluate the genital Arousal response in women with female Sexual Arousal Disorder (FSAD) after administration of sildenafil and placebo. We performed a multicenter, double‐blind, placebo‐controlled, cross‐over study to assess the clitoral engorgement response using dynamic MRI in women with FSAD after administering sildenafil and placebo followed by audiovisual Sexual stimulation (AVSS). Methods Nineteen premenopausal women with FSAD underwent two MRI sessions. Subjects were randomized to receive either (i) sildenafil 100 mg during the first session followed by placebo during the second session, or (ii) placebo followed by sildenafil. During each session, baseline MR images were obtained while subjects viewed a neutral video. Subjects then ingested sildenafil or placebo. After 30 minutes, a series of MRIs were obtained at 3‐minute intervals for 10 time points while subjects viewed AVSS. Main Outcome Measures A positive Sexual Arousal response was achieved if clitoral volume increased ≥50% from baseline. Results Thirteen of 19 (68%) subjects achieved a ≥50% increase in clitoral engorgement from baseline when administered sildenafil or placebo 30 minutes after dose administration. At 60 minutes after administration, 17/19 (89%) subjects receiving sildenafil and 16/19 (84%) subjects receiving placebo had responded ( P value 0.3173). Conclusions Sildenafil did not augment the genital response in women with FSAD. Secondarily, a majority of women in this study did not have impaired clitoral engorgement as measured by MRI, suggesting that FSAD is not predominantly a Disorder of genital engorgement. Leddy LS, Yang CC, Stuckey BG, Sudworth M, Haughie S, Sultana S, and Maravilla KR. Influence of sildenafil on genital engorgement in women with female Sexual Arousal Disorder. J Sex Med **;**:**–**.

  • ORIGINAL RESEARCH—FSD PHARMACOTHERAPY Influence of Sildenafil on Genital Engorgement in Women with Female Sexual Arousal Disorder
    2012
    Co-Authors: Laura Leddy, Claire C. Yang, Bronwyn G. A. Stuckey, Maria Sudworth, Scott Haughie, Stefan Sultana, Kenneth R. Maravilla
    Abstract:

    Introduction. We previously described dynamic, noncontrast magnetic resonance imaging (MRI) of the female genitalia as a reproducible, nonintrusive, objective means of quantifying Sexual Arousal response in women without Sexual difficulties. These studies showed an increase in clitoral engorgement ranging from 50 to 300% in healthy women during Sexual Arousal. Aim. This study sought to evaluate the genital Arousal response in women with female Sexual Arousal Disorder (FSAD) after administration of sildenafil and placebo. We performed a multicenter, double-blind, placebo- controlled, cross-over study to assess the clitoral engorgement response using dynamic MRI in women with FSAD after administering sildenafil and placebo followed by audiovisual Sexual stimulation (AVSS). Methods. Nineteen premenopausal women with FSAD underwent two MRI sessions. Subjects were randomized to receive either (i) sildenafil 100 mg during the first session followed by placebo during the second session, or (ii) placebo followed by sildenafil. During each session, baseline MR images were obtained while subjects viewed a neutral video. Subjects then ingested sildenafil or placebo. After 30 minutes, a series of MRIs were obtained at 3-minute intervals for 10 time points while subjects viewed AVSS. Main Outcome Measures. A positive Sexual Arousal response was achieved if clitoral volume increased 50% from baseline. Results. Thirteen of 19 (68%) subjects achieved a 50% increase in clitoral engorgement from baseline when administered sildenafil or placebo 30 minutes after dose administration. At 60 minutes after administration, 17/19 (89%) subjects receiving sildenafil and 16/19 (84%) subjects receiving placebo had responded (P value 0.3173). Conclusions. Sildenafil did not augment the genital response in women with FSAD. Secondarily, a majority of women in this study did not have impaired clitoral engorgement as measured by MRI, suggesting that FSAD is not predominantly a Disorder of genital engorgement. Leddy LS, Yang CC, Stuckey BG, Sudworth M, Haughie S, Sultana S, and Maravilla KR. Influence of sildenafil on genital engorgement in women with female Sexual Arousal Disorder. J Sex Med 2012;9:2693-2697.

  • original research fsd pharmacotherapy influence of sildenafil on genital engorgement in women with female Sexual Arousal Disorder
    2012
    Co-Authors: Laura Leddy, Claire C. Yang, Bronwyn G. A. Stuckey, Maria Sudworth, Scott Haughie, Stefan Sultana, Kenneth R. Maravilla
    Abstract:

    Introduction. We previously described dynamic, noncontrast magnetic resonance imaging (MRI) of the female genitalia as a reproducible, nonintrusive, objective means of quantifying Sexual Arousal response in women without Sexual difficulties. These studies showed an increase in clitoral engorgement ranging from 50 to 300% in healthy women during Sexual Arousal. Aim. This study sought to evaluate the genital Arousal response in women with female Sexual Arousal Disorder (FSAD) after administration of sildenafil and placebo. We performed a multicenter, double-blind, placebo- controlled, cross-over study to assess the clitoral engorgement response using dynamic MRI in women with FSAD after administering sildenafil and placebo followed by audiovisual Sexual stimulation (AVSS). Methods. Nineteen premenopausal women with FSAD underwent two MRI sessions. Subjects were randomized to receive either (i) sildenafil 100 mg during the first session followed by placebo during the second session, or (ii) placebo followed by sildenafil. During each session, baseline MR images were obtained while subjects viewed a neutral video. Subjects then ingested sildenafil or placebo. After 30 minutes, a series of MRIs were obtained at 3-minute intervals for 10 time points while subjects viewed AVSS. Main Outcome Measures. A positive Sexual Arousal response was achieved if clitoral volume increased 50% from baseline. Results. Thirteen of 19 (68%) subjects achieved a 50% increase in clitoral engorgement from baseline when administered sildenafil or placebo 30 minutes after dose administration. At 60 minutes after administration, 17/19 (89%) subjects receiving sildenafil and 16/19 (84%) subjects receiving placebo had responded (P value 0.3173). Conclusions. Sildenafil did not augment the genital response in women with FSAD. Secondarily, a majority of women in this study did not have impaired clitoral engorgement as measured by MRI, suggesting that FSAD is not predominantly a Disorder of genital engorgement. Leddy LS, Yang CC, Stuckey BG, Sudworth M, Haughie S, Sultana S, and Maravilla KR. Influence of sildenafil on genital engorgement in women with female Sexual Arousal Disorder. J Sex Med 2012;9:2693-2697.

  • Modeling and Simulation of Sexual Activity Daily Diary Data of Patients with Female Sexual Arousal Disorder Treated with Sildenafil Citrate (Viagra
    Pharmaceutical research, 2006
    Co-Authors: Laurent Claret, Scott Haughie, Eugene H. Cox, Lynn Mcfadyen, Alwyn Pidgen, Patrick J. Johnson, Mitra Boolell, Rene Bruno
    Abstract:

    Purpose. To develop a model to explore the dose-response of sildenafil citrate in patients with female Sexual Arousal Disorder (FSAD) based on telephone Sexual activity daily diary (TSADD) data obtained in double-blind, placebo controlled clinical studies. Materials. Data were available on 614 patients with FSAD. A parametric model (Weibull distribution) was developed to describe the probability density function of the time between Sexual events. Orgasm satisfaction scores and overall Sexual satisfaction scores were simultaneously modeled as ordered categorical variables. Simulations were performed to evaluate the expected clinical response in patients with FSAD. Results. The expected time between Sexual events was approximately 3.5 days. Satisfaction scores increased with time to achieve a plateau after 3 to 4 weeks on treatment. The expected probability of satisfying orgasm (score of 3 and higher) ranged from 34.7% for placebo to 41.6% for 100 mg sildenafil citrate. Treatment effect (difference from placebo) was 6.9% for 100 mg sildenafil citrate, ranging from 0.6 to 24.7% for testosterone levels of 0.1 to 4.0 pg/ml. The treatment effect in postmenopausal women was larger than in premenopausal women. Conclusion. A modeling and simulation framework to support drug development in FSAD was developed. Sildenafil citrate demonstrated a dose-dependent effect in patients with FSAD.

  • safety and efficacy of sildenafil citrate for the treatment of female Sexual Arousal Disorder a double blind placebo controlled study
    The Journal of Urology, 2003
    Co-Authors: Jennifer R Berman, Laura A Berman, Steven M Toler, Jennifer Gill, Scott Haughie
    Abstract:

    ABSTRACTPurpose: We evaluated the efficacy and safety of sildenafil citrate in spontaneously or surgically postmenopausal women with female Sexual Arousal Disorder (FSAD).Materials and Methods: Sildenafil (a 50 mg dose adjustable to 100 or 25 mg) was evaluated in a 12-week, double-blind, placebo controlled study in 202 postmenopausal women with FSAD who had protocol specified estradiol and free testosterone concentrations, and/or were receiving estrogen and/or androgen replacement therapy. Patients were excluded if emotional, relationship or historical abuse issues contributed significantly to Sexual dysfunction. Primary end points were questions 2 (increased genital sensation during intercourse or stimulation) and 4 (increased satisfaction with intercourse and/or foreplay) from the Female Intervention Efficacy Index (FIEI). Secondary end points were the remaining questions from this index, the Sexual Function Questionnaire and Sexual activity event log questions.Results: Significant improvements in FIEI ...